During the 44th Annual J.P. Morgan Healthcare Conference, Dianthus Therapeutics (DNTH) CEO Marino Garcia detailed the company’s progress across its pipeline and outlined key catalysts for 2026. Garcia reiterated that forward-looking statements are governed by risks disclosed in the company’s SEC filings. He emphasized DNTH’s focus on patient-friendly, infrequent subcutaneous self-administration as a core differentiator, and confirmed plans to report top-line data from the ongoing Phase I study of its second program, DNTH212, in mid-year.

DNTH’s lead asset, claseprubart, is a classical pathway C1s inhibitor with an extended eight-week half-life. Positive Phase II results in generalized myasthenia gravis were disclosed in September, showing statistically significant improvements in MG-ADL scores versus placebo at week 12. Clinical proof-of-concept signals have also emerged in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Head-to-head in vitro and clinical data support a favorable safety profile with no boxed warning requirements. The 300 mg auto-injector, designed for two- or four-week dosing, targets improved convenience over existing IV and SC biologics.

The company’s second program, DNTH212, began its Phase I dose-escalation trial in January 2026. DNTH212 is a fully humanized IgG4 monoclonal antibody that selectively targets an undisclosed immune checkpoint molecule implicated in B-cell activation. Preclinical models demonstrated dose-dependent reductions in pathogenic autoantibody titers with a projected half-life of approximately 30 days. The Phase I study will evaluate safety, tolerability and pharmacokinetics in healthy volunteers, with initial data expected by the third quarter.

Dianthus is positioned to capitalize on a growing generalized myasthenia gravis market, which recent analysis estimates at roughly 205,000 prevalent cases across major developed markets in 2024. With few approved subcutaneous complement inhibitors, claseprubart’s convenience profile may capture share from existing IV infusions. Key upcoming catalysts include the Q2 2026 Phase I readout for DNTH212, initiation of pivotal Phase III studies for claseprubart in MG, and additional data from ongoing CIDP and MMN cohorts. Management expects cash runway into late 2027, supporting multiple value-inflection events.